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ABSTRACT
Background: Diabetes mellitus in some clinical cases is accompanied with hyperalgesia. In this study, we 
evaluated the possible beneficial effect of chronic pelargonidin (PG) treatment on hyperalgesia in 
streptozotocin (STZ)-diabetic neuropathic rat. Methods: Male Wistar rats (n = 56) were divided into seven 
groups, i.e. control, diabetic, PG-treated control, PG (single- and multiple-dose)-treated diabetic, and sodium 
salicylate-treated control and diabetics. For induction of diabetes, STZ was injected i.p. at a single dose of 60
mg/kg. PG was orally administered at a dose of 10 mg/kg once and/or on alternate days for 8 weeks; 1 week 
after diabetes induction. After two months, hyperalgesia was assessed using standard formalin and hot tail 
immersion tests. Meanwhile, markers of oxidative stress in brain were measured. One-way analysis of 
variance was used for statistical analysis of the data. Results: Diabetic rats showed a marked chemical and 
thermal hyperalgesia, indicating that development of diabetic neuropathy and PG treatment (especially 
multiple-doses) significantly ameliorated the alteration in hyperalgesia (P<0.05-0.01) in diabetic rats as 
compared to untreated diabetics. PG (multiple doses) also significantly decreased diabetes-induced 
thiobarbituric acid reactive substances formation and non-significantly reversed elevation of nitrite level and 
reduction of antioxidant defensive enzyme superoxide dismutase. Conclusion: These results clearly suggest 
that PG prevents diabetic neuropathic hyperalgesia through attenuation of oxidative stress.  Iran. Biomed. J. 14
(1 & 2): 33-39, 2010
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INTRODUCTION
iabetes mellitus is one of the serious 
problems worldwide and the number of
diabetic people is estimated to be increased
markedly by the year 2030 [1]. Uncontrolled chronic
hyperglycemia in diabetes leads to severe
complications including neuropathy, retinopathy, 
and autonomic dysfunctions. Diabetic neuropathy as 
observed in some deranged conditions of 
nociception (i.e. hyperalgesia) is the most common
complication with an incidence of more than 50%
[2]. Diabetes-induced deficits in motor and sensory 
nerve conduction velocities and other manifestations 
of peripheral diabetic neuropathy have been well 
correlated with chronic hyperglycemia. 
Hyperglycemia could also lead to an increased 
oxidative stress (enhanced free radical formation 
and/or a defect in antioxidant defenses), advanced
glycation end product formation, nerve 
hypoxia/ischemia, and impaired nerve growth factor 
support [3-5].
Several studies suggest that an oxidative stress 
may be one of the major pathways in the 
development of diabetic neuropathy and antioxidant 
therapy can prevent or reverse hyperglycemia-
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induced nerve dysfunctions [6, 7]. Recent interests 
are focusing on the use of non-vitamin antioxidants 
such as flavonoids in reducing the devastating 
complications of diabetes in experimental animals 
and patients [8]. Plant-based pharmaceuticals 
including flavonoids have been employed in the 
management of various mankind diseases [8]. They 
are as an essential part of human diet and are present 
in plant extracts that have been used for centuries in 
oriental medicine. Antioxidant properties, reactive 
oxygen species (ROS) scavenging, and cell function 
modulation of flavonoids could account for the large 
part of their pharmacological activity [8, 9]. Since 
diabetes mellitus is considered as a free radical
mediated disease, there has been renewed interest in 
the use of flavonoids in diabetes research. 
Anthocyanins and their aglycone derivatives
anthocyanidins are important groups of flavonoids. 
Of these groups, pelargonidin (PG) has been 
reported to exhibit an anti-diabetic activity in 
diabetic rats [10, 11]. 
Recent reports have also demonstrated multiple 
benefits associated with the consumption of
pelargonidin-rich fruits including decreased 
vulnerability to oxidative stress, reduced ischemic 
brain damage, protection of neurons from stroke-
induced damage and the reversal of age-related 
changes in brain and behavior [12]. Berry fruits 
contain high amounts of anthocyanins, which play a 
major role as free radical scavengers which could 
inhibit H2O2-induced lipid peroxidation in the rat 
brain homogenates [13]. Therefore, we designed this 
study to investigate, for the first time, the effect of 
chronic PG treatment, a free radical scavenger on 
hyperalgesia in streptozotocin (STZ)-diabetic 
neuropathic rat, using standard formalin and hot tail 
immersion tests and also to evaluate the role of 
oxidative stress.
MATERIALS AND METHODS
Animals. Male Albino Wistar rats, weighing 215-
285 g and 10-12 weeks old, were procured from 
Pasteur Institute of Iran, Tehran. The animals were 
housed in an air-conditioned colony room on a 12/12
cycle at 21-23C with 30-40% humidity and 
supplied with a standard pelleted diet and tap water 
ad libitum. Procedures involving animals and their 
care were conducted in the conformity with NIH 
Guidelines for the Care and Use of Laboratory 
Animals.
Experimental protocol. The rats (n = 56) were 
randomly allocated and similarly grouped into seven
groups: normal vehicle-treated control, PG (multiple 
doses)- and sodium salicylate (SS)-treated control, 
vehicle-treated diabetic, PG-treated diabetics (single 
dose), PG-treated diabetics (multiple dose), and SS-
treated diabetics. SS (200 mg/kg, i.p.) was 
administered 1 h before conducting the formalin test 
as positive control.  The rats were rendered diabetic 
by a single i.p. injection of 60 mg kg-1 STZ, freshly 
dissolved in a cold normal saline. Control animals 
received an injection of an equivalent volume of 
normal saline and vehicle. Diabetes was confirmed 
by the presence of hyperglycemia, polyphagia, 
polydipsia, polyuria and weight loss. One week after 
STZ injection, the blood samples were collected and 
serum glucose concentrations were measured using
glucose oxidation method (Zistshimi, Tehran). Only 
those animals with serum glucose higher than 250
mg dl-1 were selected as diabetics for the following 
experiments. The day on which hyperglycemia had 
been confirmed was designated as day 0. PG was 
either administered once p.o. (using gavage needle) 
one week after STZ injection at a dosage of 10
mg/kg body weight (single dose) or on alternate 
days for a period of 8 weeks at the same dose 
(multiple doses). Dose of PG was selected according 
to the Roy et al. [11] on the basis of our pilot study. 
PG was dissolved in 10% cremophor with further 
dilution in distilled water before use. Changes in 
body weight, food consumption and water intake 
were regularly observed during the experimental 
period.
Formalin test. The previously described method 
was applied [14]. Briefly, each animal was 
acclimatized to the observation box before any 
testing began. Then, it was given a subcutaneous 
injection of 50 µl of 2.5% formalin into the plantar 
surface of one hind paw. It was then immediately 
placed in a Plexiglas box. Observations continued 
for the next 60 min. A nociceptive score was 
determined for 5 min blocks by measuring the 
amount of time spent in each of the four behavioral 
categories: 0, the position and posture of the injected 
hind paw is indistinguishable from the contralateral 
paw; 1, the injected paw has little or no weight 
placed on it; 2, the injected paw is elevated and is 
not in contact with any surface; 3, the injected paw 
is licked, bitten, or shaken. Then, a weighted 
nociceptive score, ranging from 0 to 3 was 
calculated by multiplying the time spent in each 
category by the category weight, summing these 
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products and dividing by the total time for each 5
min block of time. The first 10 min post-injection 
was considered as the early (first) phase and the time 
interval 15-60 as the late (second) phase.
Hot tail immersion test. Diabetic thermal 
hyperalgesia was assessed using tail immersion test
[15]. After adaptation, rat tail was immersed in 
warm water (49°C) and the tail-flick response 
latency (withdrawal response of tail) was observed 
as the endpoint response. Each experiment was 
repeated 4 times for each animal with an interval of 
2 min and its average was reported. Meanwhile, a 
cut-off time of 30 s was also considered.
Determination of brain malondialdehyde (MDA)
concentration. The rats were anesthetized with
ketamine (100 mg/kg), decapitated, the brains were 
removed, blotted dry and weighed. Then, they were 
made into 10% tissue homogenate in ice-cold 0.9%
saline solution and centrifuged (1000 ×g, 4ºC, 10
min) to remove particulates. The obtained 
supernatant was aliquoted, then stored at -80°C until 
assay. The MDA concentration (thiobarbituric acid 
reactive substances, TBARS) in the supernatant was 
measured as described before [16]. Briefly,
trichloroacetic acid and TBARS reagent were added 
to the supernatant, then mixed and incubated at 
100ºC for 80 min. After cooling on ice, the samples 
were centrifuged at 1000 ×g for 20 min and the 
absorbance of the supernatant was read at 532 nm. 
TBARS results were expressed as MDA equivalents 
using tetraethoxypropane as standard. 
Measurement of brain superoxide dismutase
(SOD) activity. The supernatant of brain 
homogenate was obtained as described earlier. SOD 
activity measurement was according to the previous 
works [16]. Briefly, supernatant was incubated with
xanthine and xanthine oxidase in potassium 
phosphate buffer (pH 7.8 at 37ºC) for 40 min and 
nitro blue tetrazolium was added. Blue formazan
was then monitored spectrophotometrically at 550
nm. The amount of protein that inhibited nitro blue 
tetrazolium reduction by 50% of maximum was
defined as 1 nitrite unit of SOD activity. 
Assay of brain nitrite concentration. Supernatant 
nitrite content was assayed by the Griess method. 
Because NO is a compound with a short half life and 
is rapidly converted to the stable end products nitrate 
(NO3-) and nitrite (NO2-), the principle of the assay 
is the conversion of nitrate into nitrite by cadmium 
and followed by color development with Griess 
reagent (sulfanilamide and N-naphthyl 
ethylenediamine) in acidic medium. The total nitrite 
was measured by Griess reaction. The absorbance 
was determined at 540 nm with a spectrophotometer.
Protein assay. The protein content of the 
supernatant was measured with Bradford method 
using bovine serum albumin (Sigma Chemical, St. 
Louis, MO) as the standard [17].  
Chemicals. PG, cremephor and reagents for 
oxidative stress assessment were purchased from 
Sigma Chemical and Fluka (St. Louis, Mo., USA).
SS was obtained from Darupakhsh (Tehran, Iran) 
and STZ from Pharmacia and Upjohn (USA). All 
other chemicals were purchased from Merck 
(Germany) and Temad (Tehran). 
Statistical analysis. All results are expressed as 
means ± S.E.M. For multiple comparisons, one-way 
analysis of variance (ANOVA) was used. When 
ANOVA showed a significant difference, Tukey's
post hoc test was applied. Statistical significance 
was regarded as P<0.05.
RESULTS
General considerations. Two rats died in diabetic 
groups at 2nd week after STZ injection due to 
possibly cytotoxic effect of the drug and one rat was 
excluded at final weeks of the study due to severe 
weight loss and immotility. Meanwhile, 77.5% of 
rats were made diabetic following STZ injection and 
had a serum glucose level higher than 250 mg/dl. 
After 8 weeks, the weight of the vehicle-treated 
diabetic rats was found to be significantly decreased 
as compared to control rats (P<0.01) and PG 
treatment (single and multiple doses) caused a less 
significant decrease in diabetic rats as compared to 
diabetics (P<0.05-0.01). In this respect, PG 
administration for 8 weeks (multiple doses) was 
more effective in preventing weight loss than its 
single dose. In addition, diabetic rats had also an 
elevated serum glucose level over those of control 
rats (P<0.001) and treatment of diabetic rats with PG 
(single and multiple doses) caused a significant 
decrease in the serum glucose (P<0.01-0.005) 
relative to vehicle-treated diabetics. Again, PG 
administration for 8 weeks was more effective in 
serum glucose reduction than its single dose. 
Meanwhile, PG treatment of control rats did not 
produce any significant change regarding serum 
glucose level (Fig. 1).
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Formalin test. Hind limb formalin injection 
produced a marked biphasic response in the rats of 
all groups (Fig. 2). Hyperalgesia was significantly 
(P<0.05) greater in untreated diabetics than in 
control rats in early and late phases of the test. Pre-
treatment of control and diabetic rats with SS (200
mg/kg, i.p.) 1 hour before the test caused a 
significant reduction (P<0.01) in nociceptive score 
only in the second phase of the formalin test. In 
addition, treatment of diabetic rats with PG (10
mg/kg), especially with its multiple-dose caused 
lower nociceptive scores in both phases of the 
formalin test as compared to vehicle-treated diabetic 
rats (P<0.05-0.01). No such response was observed 
for PG-treated controls. 
Fig. 1. Body weight and serum glucose concentration in 
different weeks (means ± S.E.M). **P<0.01, ***P<0.005, **** 
P<0.0001 (as compared to week 0 in the same group); #P<0.05, 
##P<0.01, ###P<0.005 (as compared to diabetics in the same 
week). PG stands for pelargonidin.
Thermal hyperalgesia. A significant decrease in 
tail-flick latency was observed after two months of 
diabetes in hot tail immersion test (P<0.05) (Fig. 3). 
This deficit in   tail-flick   response latency was 
Fig. 2. The effect of pelargonidin and sodium salicylate on 
nociceptive scores in the first (early) and second (late) phases of 
the formalin test. All data represent mean ± S.E.M. *P<0.05, 
**P<0.01 (as compared to control); #P<0.05, ##P<0.01 (as 
compared to diabetic).
significantly reversed on treatment with 
PG, especially again with its multiple dose 
(P<0.05).
Markers of oxidative stress. Regarding brain lipid 
peroxidation and oxidative stress markers (Figs. 4-
6), STZ-induced diabetes resulted in significant
elevation of MDA and nitric oxide content (P<0.05) 
and non-significant reduction of SOD activity and 
treatment of diabetic rats with PG (multiple doses) 
significantly attenuated the increased MDA content
(P<0.05). However, level of SOD was non-
significantly higher and level of nitrite was lower in 
PG-treated diabetics as compared to diabetic group.
Fig. 3. The effect of pelargonidin (PG) treatment on 
hyperalgesia in hot tail immersion test. All data represent mean 
± S.E.M. *P<0.05 (as compared to control); # P<0.05 (as 
compared to diabetic).
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Fig. 4. MDA concentration in whole brain homogenate from 
different groups. *P<0.05 (as compared to controls); #P<0.05 (as 
compared to diabetics). PG stands for pelargonidin.
DISCUSSION
In this study, development of diabetic neuropathy 
in STZ-induced diabetic rats was confirmed after 
two months, which was consistent with previous 
reports [18]. It has been well established that 
oxidative stress finally leads to nerve deficits in 
diabetic rats [7]. Some studies indicated that a 
hypoxic mechanism is involved in peripheral 
diabetic neuropathy. Decreased nerve blood flow 
and ensuring endoneurial hypoxia may cause 
functional and morphological abnormalities of 
nervous system [4]. In addition, increased free
radicals due to hyperglycemia may affect central and 
peripheral nervous system [19]. Furthermore, there 
is some evidence for involvement of sorbitol 
pathway related to glucose metabolism in the 
pathogenesis of diabetic neuropathy [3].
In this study, we observed a reduction in tail-flick 
latencies in hot immersion  test   in diabetic  rats,
Fig. 5. Superoxide dismutase activity in whole brain 
homogenate from different groups. PG stands for pelargonidin.
which indicates thermal hyperalgesia. Several 
researchers have reported hyperalgesia in diabetic 
rats [20, 21]. Such mechanisms including tissue 
injury due to ischemia, sensitization of peripheral 
receptors and ectopic activity in sprouting fibers and 
alterations in dorsal root ganglia cells have been 
reported to contribute to changes in nociception
[22]. It is a well-established fact that diabetic rats 
display exaggerated hyperalgesic behavior in 
response to noxious stimuli that may model aspects 
of painful diabetic neuropathy [23]. For this reason, 
STZ-diabetic rats have been increasingly used as a 
model of painful diabetic neuropathy to assess 
the   efficacy  of   potential analgesic  agents [24].
Fig. 6. Nitrite content in whole brain homogenate from 
different groups. *P<0.05 (as compared to controls). PG stands
for pelargonidin.
Although mechanisms causing these symptoms are 
complicated, direct toxicity of hyperglycemia in the 
peripheral nervous system [25], an increased activity 
of primary afferent fibers, increased release of 
glutamate, reduced activity of both opioidergic and 
GABAergic inhibitory systems [26], altered both 
sensitivity of the dopaminergic receptors and 
responsiveness of the dopaminergic system (possibly 
through endogenous enkephalinergic system) [27]
and also alterations in L-type Ca2+ channels [28] are 
involved in the modulation of nociception in diabetic 
rats. 
Increased free radical mediated toxicity has also 
been well documented in clinical diabetes [29] and 
STZ-diabetic rats [30]. The elevated level of toxic 
oxidants in diabetic state may be due to the 
processes such as glucose oxidation and lipid 
peroxidation [29]. STZ-diabetes is also characterized 
by several derangements in endogenous antioxidant 
enzymes [29] and induction of antioxidant enzymes 
is a critical approach for protecting cells against a 
variety of endogenous and exogenous toxic 
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compounds such as reactive oxygen species [30].
Increased level of MDA and a reduction in the 
activity of SOD were observed in diabetic rats in our 
study which might be due to the increased lipid 
peroxidation and overproduction of ROS, which is 
in agreement with the previous report [29]. 
Oral administration of PG for two months in our 
study also produced a significant analgesic effect at
both phases of the formalin test only in diabetic rats
and SS significantly reduced the nociceptive score 
only in the second phase of the formalin test in 
control and diabetic rats. It has been known that 
central-acting drugs like narcotics inhibit both 
phases of the formalin test equally [31], while 
peripheral-acting drugs like aspirin only inhibit the 
late phase [32]. Therefore, the effect of PG in this 
study could be mediated possibly through a central 
and/or a peripheral mechanism. One of the possible 
mechanisms that could partially explain the 
beneficial analgesic property of PG may be 
attributed to its hypoglycemic and antioxidant 
effects. Since hyperglycemia in diabetic state could 
induce some functional alterations in the nervous 
system [21], PG may have attenuated the 
hyperalgesic condition in formalin test.
The results of the present study also showed that 
PG administration could exert an anti-hyperglycemic
effect in diabetic rats and not in control 
normoglycemic rats. Blood glucose level is mainly 
controlled by insulin secretion from pancreatic β 
cells and insulin action on liver, muscle and other 
target tissues. STZ destroys pancreatic β cells by 
different mechanisms such as DNA damage through 
alkylation, depletion of NAD+, and generation of 
ROS species to induce type 1diabetes. Decrease in 
elevated blood glucose and normalization of glucose 
tolerance curve in diabetics following PG have been 
attributed to the stimulatory activity of PG by 
protecting β cells of islets of Langerhans and 
enhancing their functions in diabetic rats [11, 33].
PG may have protected and stimulated pancreatic β
cells by its antioxidant activity and/or by other 
activities like modulation of gene expression and 
interaction with signal transduction pathways, 
leading to insulin release in diabetic rats [11].
However, PG does not change insulin level and 
other biochemical parameters in control rats to 
maintain their physiological balance. A similar result
has been obtained with other flavonoids, which had 
almost no effects on glycemic status and oxidative 
stress markers in normal rats, but showed significant 
effects on these parameters in STZ-treated rats [34].
Overall, PG showed an anti-hyperglycemic and 
protective effect on diabetic neuropathy as it was 
evident from a reduction in chemical and thermal 
hyperalgesia in treated diabetic rats and it seems that 
PG may be a good adjuvant in the present 
armamentarium of anti-diabetic drugs to prevent the 
development of some diabetic complications.
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